Krishna Gorti

Former Analyst at JP Morgan Securities LLC

Krishna Gorti

Krishna Gorti

Former Analyst at JP Morgan Securities LLC

Overview
RelSci Relationships

1352

Contact Data
Trying to get in touch with Krishna Gorti? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Krishna Gorti likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Research Analyst at Robert W. Baird & Co., Inc. (Broker)

Relationship likelihood: Average

Former Managing Director & Senior Biotechnology Analyst at H. C. Wainwright & Co. LLC

Relationship likelihood: Average

Managing Director & Senior Medical Technology Analyst at Oppenheimer & Co., Inc.

Relationship likelihood: Average

Former Analyst at JP Morgan Securities LLC

Relationship likelihood: Average

Former Executive Coordinator at Rodman & Renshaw LLC (Old)

Relationship likelihood: Weak

Managing Director in Equity Research at Ladenburg Thalmann & Co., Inc.

Relationship likelihood: Weak

Former Vice President at Rodman & Renshaw LLC (Old)

Relationship likelihood: Weak

Former Vice President at Rodman & Renshaw LLC (Old)

Relationship likelihood: Weak

Former Roadshow Coordinator at Rodman & Renshaw LLC (Old)

Relationship likelihood: Weak

Former Financial Advisor at Rodman & Renshaw LLC (Old)

Relationship likelihood: Weak

Paths to Krishna Gorti
Potential Connections via
Relationship Science
You
Krishna Gorti
Former Analyst at JP Morgan Securities LLC
Education

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Career History
Research Analyst
2009 - 2010

Founded in 1969, Piper Jaffray & Co. (NYSE: PJC) is an international, middle-market investment bank and institutional securities firm headquartered in Minneapolis, Minnesota. The firm's products and services include equity and public finance underwriting, mergers and acquisitions, equity and debt capital markets, high-yield and structured products, institutional equity, tax-exempt and taxable sales and trading and equity and high-yield research. Their clients include corporations, private equity groups, public entities, nonprofit entities and institutional investors.PJC's Equity Sales & Trading division provides institutional sales, trading and research services for various equity and fixed income products. Their research includes fundamental and technical analysis. PJC's equity business focuses on the business & financial services, clean tech industrials, consumer, healthcare and technology sectors.Through their traditional and electronic trading platforms, PJC offers clients a broad array of taxable and tax-exempt fixed income products including government and agency securities, CDs, commercial paper, convertible bonds, corporate bonds, loans, money-market securities, MBS & ABS, municipal bonds, preferred stock, repurchase agreements and variable-, auction- and fixed-rated securities.

Analyst
2010 - 2011

J.P. Morgan Securities offers a broad array of investment products and the world’s leading investment managers. These expansive resources—the best people and products in the industry coupled with a Financial Advisor who is directly involved in the investment process—are the true benefits of working with it.

Professional
Prior

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Krishna Gorti. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Krishna Gorti's profile does not indicate a business or promotional relationship of any kind between RelSci and Krishna Gorti.